Biomolecular Discovery Services

Biomolecular Discovery Services

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Biomolecular Discovery Services is a specialized contract research provider founded in 2005, headquartered in Rochester, NY. The company's core expertise lies in phage display-based antibody discovery, offering services ranging from library creation and screening to antibody engineering and affinity maturation. It has developed a strong niche in VHH (nanobody) discovery from both synthetic and immunized camelid sources. As a service-based CRO, its business model is built on providing tailored research solutions to biopharma clients, positioning it in the growing biologics discovery outsourcing market.

Drug DeliverySmall MoleculesProteomics

Technology Platform

Phage display technology for antibody discovery, specializing in synthetic and immunized VHH (nanobody) libraries, coupled with next-generation sequencing (NGS) analysis.

Opportunities

Growing demand for antibody discovery outsourcing, especially for niche modalities like VHH nanobodies.
The company's U.S.-based operations and integration of NGS with phage display provide competitive differentiation.
The expanding biologics market creates a sustained need for specialized CRO services.

Risk Factors

Revenue is project-based and subject to variability from biopharma R&D spending cycles.
Faces intense competition from larger CROs and other niche players.
Risk of technological disruption from newer display technologies or computational design platforms.

Competitive Landscape

Competes in the fragmented antibody discovery CRO market against large, full-service life science CROs and numerous small, specialized firms. Differentiation is based on deep expertise in VHH/phage display, U.S. operations, and NGS integration. Must continually demonstrate value and technical success to retain clients.